KRAS and non-small cell lung carcinoma: In the pilot phase 2 trial, NCT02716038, of neoadjuvant atezolizumab and chemotherapy in resectable NSCLC, ten patients had known oncogenic drive alterations (STK11, 2; KRAS, 2; KRAS/STK11, 1; EGFR, 4; and HER2, 1).